Lifeblood Medical, Inc. Announces Submission and Receipt of Drug Master File for Lifor(R)

ADELPHIA, NJ--(Marketwire - June 01, 2009) -

Lifeblood Medical, Inc. has completed an important strategic plan towards entering the Tissue Preservation market with Lifor® ACF Perfusion Media by filing a Drug Master File (DMF) with the United States Food and Drug Administration (FDA). Lifeblood has received confirmation and a DMF control number from the FDA

“This is an important strategic move for Lifeblood in obtaining our 510k clearance for use of Lifor® for Tissue Preservation within the allograft market,” said Joseph Fischer, President and Chief Executive Officer. “The fact that Lifor® is Animal Component Free (ACF), can extend preservation time at elevated temperatures and provide oxygen to cells, tissues and organs will make it the choice for allograft processing companies. We also believe that the Lifor® swine limb preservation study (abstract entitled Lifor® as a Limb Preservation for Battlefield Situations) conducted this year by one of our collaborators will enable the field of Composite Tissue Allotransplantation to become readily available and enhance the gift of tissue donation.”

The application to the FDA provides key information about the quality of components, materials and manufacturing processes involved in producing Lifor®.

“The DMF is also an important step in our commercialization strategy of Lifor®'s potential to be used in a drug or regulated manufacturing environment by our customers. We are currently in discussions to license and sell Lifor® internationally for applications other than Tissue Preservation. A DMF will help expedite these collaborations, as well as increase awareness and interest,” said Joseph Fischer.

About Lifor®

Lifor® solution technology is a proprietary, patented Animal Component Free room temperature preservation medium. Lifor® has the capability to carry oxygen and nutrients to cells, tissues and organs. These unique characteristics not only allows Lifor® to sustain metabolic processes and keep cells alive, which is a critical factor in organ preservation, but creates an in vivo-like physiologic state for organs separated from a normal blood supply.

Lifeblood Medical, Inc. - Novel Solutions for Cell Therapy and Regenerative Medicine

Lifeblood Medical, Inc. owns a patented technology that has solved the basic properties of preserving and nourishing cells without animal based components or toxic side effects. This discovery allows the Company to penetrate multiple biotech and biopharmaceutical markets. The Additional information is available at www.lifebloodmedical.com.

Lifor® is a registered trademark of Lifeblood Medical, Inc.